Mankind Pharma share news and announcements

NSE: MANKINDBSE: 543904Pharmaceuticals & BiotechnologyMid Cap

₹2,212.60₹63.00 (2.77%)BSE ₹2,217.00

Share price at the NSE close on 23 Oct 2026. Previous close ₹2,275.60.

52-week range of traded prices to 23 Oct 2026

₹1,909.70Low, 23 Mar 2026₹2,642.00High, 29 Jul 2026

Next results date: the board meets on 26 Oct 2026 to consider: financial results.

Market cap: ₹91,390 Cr119th largest listed
P/E: 44.6
P/B: 5.6
Dividend yield: Nonein the last 12 months
ROE: 13.4%
ROCE: 12.8%
Debt to equity: 0.38
Volume, NSE: 6,79,10661.7% delivered

Mankind Pharma board meetings

39 filed, newest first.

Oct 2026
- 15 Oct · Board meeting
  Outcome of Board Meeting held on October 15, 2026. (opens in a new tab)
- 8 Oct · Board meeting
  To consider and approve the financial results for the period ended September 30, 2026 (opens in a new tab)
Aug 2026
- 26 Aug · Board meeting
  Please find attached outcome of Board Meeting held today, according consent of the Board of Directors of the Company for the integration of Bharat Serums and Vaccines Limtied, a wholly owned material subsidiary, into the Company by way of voluntary liquidation. (opens in a new tab)
- 10 Aug · Board meeting
  Outcome of Board Meeting held on August 10, 2026. (opens in a new tab)
Jul 2026
- 16 Jul · Board meeting
  To consider and approve the financial results for the period ended Jun 30, 2026 (opens in a new tab)
- 11 Jul · Board meeting
  Outcome of Board Meeting held on July 11, 2026. (opens in a new tab)
May 2026
- 7 May · Board meeting
  To consider and approve the financial results for the period ended March 31, 2026 (opens in a new tab)
Apr 2026
- 13 Apr · Board meeting
  Outcome of Board Meeting held on April 13, 2026. (opens in a new tab)
Feb 2026
- 3 Feb · Board meeting
  Board meeting held on February 03, 2026. (opens in a new tab)
Jan 2026
- 9 Jan · Board meeting
  To consider and approve the financial results for the period ended December 31, 2025 (opens in a new tab)
Nov 2025
- 6 Nov · Board meeting
  Board meeting held on November 06, 2025. (opens in a new tab)
Oct 2025
- 27 Oct · Board meeting
  To consider and approve the financial results for the period ended September 30, 2025 (opens in a new tab)
Jul 2025
- 14 Jul · Board meeting
  To consider and approve the financial results for the period ended Jun 30, 2025 and dividend (opens in a new tab)
May 2025
- 8 May · Board meeting
  We wish to inform you that a meeting of Board of Directors of the Company is scheduled to be held on Wednesday, May 21, 2025, inter-alia to consider and approve the standalone and consolidated audited financial results of the Company for the quarter and financial year ended on March 31, 2025.Further, in continuation of our earlier letter dated March 26, 2025 under subject Closure of Trading Window under SEBI (Prohibition of Insider Trading) Regulations, 2015 and the Company's 'Code of Conduct for Prevention of Insider Trading', the trading window for trading in the securities of the Company shall remain closed till May 23, 2025 (opens in a new tab)
Apr 2025
- 14 Apr · Board meeting
  Board meeting held on April 14, 2025. (opens in a new tab)
Feb 2025
- 10 Feb · Board meeting
  Sale of entire stake in Mahananda Spa and Resorts Private Limited (opens in a new tab)
Jan 2025
- 23 Jan · Board meeting
  Outcome of Board Meeting held today i.e. January 23, 2025 (opens in a new tab)
- 13 Jan · Board meeting
  To consider and approve the unaudited financial results for the quarter and nine months ended on December 31, 2024 (opens in a new tab)
- 8 Jan · Board meeting
  Board meeting held on January 08, 2025. (opens in a new tab)
Dec 2024
- 3 Dec · Board meeting
  Board meeting held on December 03, 2024. (opens in a new tab)
Nov 2024
- 5 Nov · Board meeting
  Outcome of Board Meeting held today i.e. November 5, 2024 (opens in a new tab)
Oct 2024
- 25 Oct · Board meeting
  To consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter and half year ended on September 30, 2024 (opens in a new tab)
Sep 2024
- 30 Sep · Board meeting
  Outcome of Fund Raising Committee Meeting held today i.e. September 30, 2024 (opens in a new tab)
- 20 Sep · Board meeting
  Outcome of Board Meeting held today i.e. September 20, 2024 (opens in a new tab)
- 17 Sep · Board meeting
  We wish to inform you that a meeting of Board of Directors of the Companywill be held on September 20, 2024, inter-alia to consider and approve the raising of funds byway of issue of non-convertible debentures, commercial papers, other debt securities or any othersecurity or any combination thereof for an amount as may be decided by the Board. (opens in a new tab)
Jul 2024
- 18 Jul · Board meeting
  We wish to inform you that a meeting of Board of Directors of the Company will be held on Wednesday, July 31, 2024, inter-alia to consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter ended on June 30, 2024. (opens in a new tab)
May 2024
- 15 May · Board meeting
  Outcome of Board meeting held today i.e. May 15, 2024. (opens in a new tab)
- 8 May · Board meeting
  To consider and approve the financial results for the period ended March 31, 2024 and to evaluate various options or proposals for raising funds through any of the permissible modes, subject to the receipt of necessary approvals. (opens in a new tab)
Apr 2024
- 2 Apr · Board meeting
  Board of Directors of the Company at its meeting held today i.e. April 2, 2024, has inter-alia,considered and approved the following:1. Slump sale of the Over the Counter ( OTC ) Business of the Company to Wholly OwnedSubsidiary Company proposed to be incorporated with the name of Mankind ConsumerProducts Private Limited or any other name as approved by Ministry of Corporate Affairs. Thetransaction will be effective on or before October 1, 2024 or such other date as may be mutuallyagreed between the parties, subject to customary closing conditions. The Company willcontinue to have business operations with the proposed incorporated entity on arm s lengthbasis.2. Incorporation of a wholly owned subsidiary by the name Mankind Consumer Products PrivateLimited or any other name approved by Registrar of Companies, Ministry of Corporate Affairs. (opens in a new tab)
- 2 Apr · Board meeting
  Board of Directors of the Company at its meeting held today i.e. April 2, 2024, has inter-alia, considered and approved the following:1. Slump sale of the Over the Counter ( OTC ) Business of the Company to Wholly Owned Subsidiary Company proposed to be incorporated with the name of Mankind Consumer Products Private Limited or any other name as approved by Ministry of Corporate Affairs. The transaction will be effective on or before October 1, 2024 or such other date as may be mutually agreed between the parties, subject to customary closing conditions. The Company will continue to have business operations with the proposed incorporated entity on arm s length basis. 2. Incorporation of a wholly owned subsidiary by the name Mankind Consumer Products Private Limited or any other name approved by Registrar of Companies, Ministry of Corporate Affairs. (opens in a new tab)
Jan 2024
- 31 Jan · Board meeting
  Outcome of Board Meeting held today i.e. January 31, 2024 (opens in a new tab)
- 16 Jan · Board meeting
  We hereby inform you that a meeting of Board of Directors of the Company will be held on Wednesday, January 31, 2024, inter-alia to consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter and nine months ended on December 31, 2023.Further, in continuation of our earlier letter dated December 27, 2023 under subject Closure of Trading Window under SEBI (Prohibition of Insider Trading) Regulations, 2015 and the Company's 'Code of Conduct for Prevention of Insider Trading', the trading window for trading in the securities of the Company shall remain closed till February 02, 2024.The above notice and details are also being uploaded on the website of the Company at www.mankindpharma.com. (opens in a new tab)
Oct 2023
- 31 Oct · Board meeting
  Board meeting held on October 31, 2023. (opens in a new tab)
- 11 Oct · Board meeting
  We hereby inform you that a meeting of Board of Directors of the Company will be held on Tuesday, October 31, 2023, inter-alia to consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter and half year ended on September 30, 2023.Further, in continuation of our earlier letter dated September 27, 2023 under subject Closure of Trading Window under SEBI (Prohibition of Insider Trading) Regulations, 2015 and the Company's 'Code of Conduct for Prevention of Insider Trading', the trading window for trading in the securities of the Company shall remain closed till November 02, 2023.The above notice and details are also being uploaded on the website of the Company at www.mankindpharma.com. (opens in a new tab)
Aug 2023
- 2 Aug · Board meeting
  Outcome of Board Meeting held today i.e. August 2, 2023. (opens in a new tab)
Jul 2023
- 18 Jul · Board meeting
  We hereby inform you that a meeting of Board of Directors of the Company will be held on Wednesday, 2nd August 2023, inter-alia to consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter ended on 30th June 2023. (opens in a new tab)
May 2023
- 30 May · Board meeting
  Board of Directors of the Company at its meeting held today i.e. 30th May 2023, has inter-alia, considered and approved the following:1. The Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ended on 31st March 20232. Re-Appointment of M/s. M.K. Kulshrestha & Associates, Cost Accountants as the Cost Auditors of the Company for the Financial Year 2023-243. Appointment of Mr. Anil Gupta, Associate Vice President & Head Internal Audit as the Internal Auditor of the Company with effect from Financial Year 2023-24 in place of retiring Internal Auditor M/s Ghosh Khanna & Co. LLP, Chartered Accountants (opens in a new tab)
- 30 May · Board meeting
  Board of Directors of the Company at its meeting held today i.e. 30th May 2023 has inter-alia approved the Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ended on 31st March 2023.We are enclosing herewith as follows:a. Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ended on 31st March 2023; b. Auditors report with unmodified opinion on the audited Standalone and Consolidated Financial Results of the Company for the financial year ended on 31st March 2023; and c. The declaration from Chief Financial Officer pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements), 2015, Regulations confirming the unmodified opinion of the statutory auditors on the audited Standalone and Consolidated Financial Results of the Company for the financial year ended on 31st March 2023. (opens in a new tab)
- 22 May · Board meeting
  To consider and approve the financial results for the period ended March 31, 2023 (opens in a new tab)

Mankind Pharma board meetings

Oct 2026

Aug 2026

Jul 2026

May 2026

Apr 2026

Feb 2026

Jan 2026

Nov 2025

Oct 2025

Jul 2025

May 2025

Apr 2025

Feb 2025

Jan 2025

Dec 2024

Nov 2024

Oct 2024

Sep 2024

Jul 2024

May 2024

Apr 2024

Jan 2024

Oct 2023

Aug 2023

Jul 2023

May 2023